Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance

Debonnaire P, Zwetsloot PP, Pfister R, Llàcer P, Cipriani A, Milani P, Bonderman D, Ohlmeier C, Evers T, Wyss R, Patorno E, Doshi R, Beisel[...]

Vershel C, Kim S, Gensler LS, Brown MA, Weisman MH, Ishimori ML, Ward M, Reveille JD, Hwang MC. Examining the Interchangeability of Two Different Patient-Reported[...]

Rutkovskis E, Ravagli E, Lancashire HT, Shah Idil A, Thompson N, Perkins JD, Challita R, Hadaya J, Vivekananda U, Ajijola O, Shivkumar K, Miserocchi A,[...]